Mayne Pharma Discloses Exit of Director Patrick Blake and His Share Interests

The latest update is out from Mayne Pharma Group ( (AU:MYX) ).

Mayne Pharma Group has announced that director Patrick J. Blake ceased to be a director of the company effective 28 February 2026. The filing details that Blake held no shares directly in his own name but had an indirect interest in 22,097 ordinary shares through The Patrick J Blake Trust, with no disclosed interests in any related contracts.

The change in board composition signals a governance shift for Mayne Pharma, though the notice indicates no complex financial arrangements tied to Blake’s departure. Stakeholders will note that the only recorded equity exposure associated with the outgoing director is via the family trust, suggesting limited direct alignment through personal shareholdings at the time of his exit.

The most recent analyst rating on (AU:MYX) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.

More about Mayne Pharma Group

Mayne Pharma Group Limited is an Australian pharmaceutical company that develops and manufactures specialty and generic medicines. The company focuses on oral drug delivery systems and supplies products to both domestic and international markets, targeting healthcare providers, pharmacies, and patients with a range of prescription treatments.

YTD Price Performance: -18.97%

Average Trading Volume: 444,439

Technical Sentiment Signal: Sell

Current Market Cap: A$204.7M

For detailed information about MYX stock, go to TipRanks’ Stock Analysis page.